8-K: Neuraxis Secures $3 Million in Convertible Note Financing, Amends Preferred Stock Terms

Neuraxis, Inc. has entered into a securities purchase agreement for $3 million in convertible notes and amended the terms of its Series B Preferred Stock.

Summary

• Neuraxis, Inc. has secured approximately $3 million through a securities purchase agreement with three related institutional accredited investors.
• The financing involves the issuance of convertible promissory notes with an 8.5% annual interest rate, payable quarterly in cash or common stock at a conversion price of $2.38 per share.
• The notes will automatically convert into Series B Preferred Stock upon stockholder approval and the filing of the Certificate of Designation.
• The company has increased the number of Series B Preferred Stock shares from 1,500,000 to 4,000,000 and changed the stated value from $1.00 to $2.38 per share.
• Dividend and liquidation rights for the Series B Preferred Stock will expire on June 30, 2025.
• The conversion of Series B Preferred Stock into common stock is capped at a maximum percentage, initially between 4.99% and 19.99%, of the outstanding common stock until stockholder approval is obtained.
• If stockholder approval is not obtained by August 15, 2024, the investors can convert the notes into common stock at $2.38 per share.
• The company has also amended warrants held by over 70% of holders to waive their right to receive extra shares upon a reduction of the exercise price.

Sentiment

Score: 6

Explanation: The document indicates a positive development with the securing of $3 million in funding, but there are some risks and limitations associated with the terms of the financing, such as the expiration of dividend rights and the conversion cap. The sentiment is therefore moderately positive.

Positives

• The $3 million in funding provides Neuraxis with additional working capital.
• The conversion price of $2.38 per share for both the notes and preferred stock provides a clear valuation point.
• The amendment of the warrants removes a potential dilution risk for existing shareholders.
• The company has secured funding from related institutional investors, indicating confidence in the company's prospects.

Negatives

• The dividend and liquidation rights for the Series B Preferred Stock expire on June 30, 2025, which may be a concern for investors.
• The conversion cap on the Series B Preferred Stock may limit the potential upside for investors.
• The company's failure to obtain stockholder approval by August 15, 2024, could lead to the conversion of notes into common stock, potentially diluting existing shareholders.

Risks

• The company's ability to obtain stockholder approval for the Series B Preferred Stock is critical for the conversion of the notes.
• Failure to obtain stockholder approval by August 15, 2024, will trigger a conversion of the notes into common stock at $2.38 per share, potentially diluting existing shareholders.
• The expiration of dividend and liquidation rights for the Series B Preferred Stock on June 30, 2025, could impact investor returns.
• The conversion cap on the Series B Preferred Stock may limit the potential upside for investors.

Future Outlook

The company is seeking stockholder approval for the creation of the Series B Preferred Stock, which is critical for the conversion of the notes. The company is also required to file a resale registration statement for the common stock underlying the preferred stock within 15 business days of obtaining stockholder approval.

Industry Context

This financing is typical for a company seeking to raise capital for working capital and general corporate purposes. The use of convertible notes and preferred stock is a common method for early-stage companies to attract investors.

Comparison to Industry Standards

• The 8.5% interest rate on the convertible notes is within the typical range for similar financings in the current market.
• The conversion price of $2.38 per share is a key valuation point, and the cap on conversion to common stock is a common feature to protect existing shareholders from excessive dilution.
• The use of a resale registration statement is standard practice to allow investors to sell their shares in the public market.
• The terms of the Series B Preferred Stock, including the expiration of dividend and liquidation rights, are not uncommon in venture capital and private equity financings.

Related Party Transactions

• The securities purchase agreement is with three related institutional accredited investors.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into common stock due to the failure to obtain stockholder approval.
• Investors in the convertible notes and Series B Preferred Stock will have the potential for returns based on the conversion price and the company's performance.
• Employees may benefit from the company's increased financial stability and ability to execute its business plan.

Next Steps

• The company needs to obtain stockholder approval for the creation of the Series B Preferred Stock.
• The company needs to file a resale registration statement for the common stock underlying the preferred stock within 15 business days of obtaining stockholder approval.
• The company needs to ensure compliance with all terms of the securities purchase agreement and related agreements.

Key Dates

Keywords

convertible notes, Series B Preferred Stock, securities purchase agreement, financing, stockholder approval, warrants, conversion price, common stock, institutional investors, dilution